Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation

American Journal of Transplantation

Volumn 6, Issue 8, 2006, Pages 1841-1847

  Gloor, J M ^a   Cosio, F G ^a   Rea, D J ^a   Wadei, H M ^a   Winters, J L ^a   Moore, S B ^a   DeGoey, S R ^a   Lager, D J ^a   Grande, J P ^a   Stegall, M D ^a  

^a MAYO CLINIC   (United States)

Author keywords

ABO incompatible; Kidney transplantation; Positive crossmatch

Indexed keywords

ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GLOMERULOPATHY; HISTOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ABO BLOOD-GROUP SYSTEM; BIOPSY; BLOOD GROUP INCOMPATIBILITY; COMPLEMENT C4; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 33745782746     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01416.x     Document Type: Article

References (33)

1. Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living donor kidney transplantation. Am J Transplant 2003; 3: 1017-1023.
2. Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulin. Am J Transplant 2002; 2: 758-760.
3. Jordan SC, Vo A, Bunnapradist S et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631-636.
4. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
5. Akalin E, Ames S, Sehgal V et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell cross-match positive patients. Transplantation 2003; 76: 1444-1447.
6. Schweitzer E, Wilson JS, Fernandez-Vina M et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 1531-1536.
7. Gloor JM, Lager DJ, Moore SB et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75: 971-977.
8. Tanabe K, Takahashi K, Sonda K et al. Long-term results of ABO-incompatible living kidney transplantation. Transplantation 1998; 65: 224-228.
9. Nelson PW, Landreneau MD, Luger AM et al. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation 1998; 65: 256-269.
10. Lee P-C, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2003; 74: 1192-1194.
11. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria- an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
12. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T. The Banff 97 working classification for renal allograft pathology. Kidney Int 1999; 55: 713-723.
13. Gloor JM, DeGoey S, Ploeger N et al. Persistence of low levels of alloantibody after desensitization in crossmatch positive living donor kidney transplantation. Transplantation 2003; 78: 221-227.
14. Wilson DM, Bergert JH, Larson TS, Liedtke RR. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 1997; 30: 646-652.
15. Levey AS, Greene T, Schluchter MD. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993; 4: 1159-1171.
16. Fidler ME, Gloor JM, Lager DJ et al. Histologic findings of antibody mediated rejection in ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2003; 4: 101-107.
17. Winters JL, Gloor JM, Pineda AA, Stegall MD, Moore SB. Plasma exchange conditioning for ABO-incompatible kidney transplantation. J Clin Apheresis 2004; 19: 1-7.
18. Stegall MD, Gloor JM, Winters J, Moore SB. A Comparison of plasmapheresis vs high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2005; 6: 346-351.
19. Cosio FG, Grande JP, Larson TS et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005; 5: 1-7.
20. Habib R, Broyer M. Clinical significance of allograft glomerulopathy. Kidney Int 1993; 43(Suppl): S95-S98.
21. Monga G, Mazzucco G, Novara R, Reale L. Intertubular capillary changes in kidney allografts: An ultrastructural study in patients with transplant glomerulopathy. Ultrastruct Pathol 1990; 14: 201-209.
22. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
23. Habib R, Zurowska A, Hinglais N et al. A specific glomerular lesion of the graft: Allograft glomerulopathy. Kidney Int 1993; 44(Suppl): S104-S111.
24. Horita S, Nitta K, Kawashima M et al. C4d deposition in the glomeruli and peritubular capillaries associated with transplant glomerulopathy. Clin Transplant 2003; 17: 325-330.
25. Slipkens YW, Joosten SA, Wong M-C et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65: 2409-2418.
26. Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 2000; 70: 1331-1335.
27. Shimmura H, Tanabe K, Ishida H et al. Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation 2005; 80: 985-988.
28. Gloor JM, Lager DJ, Fidler ME et al. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80: 1572-1577.
29. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-228.
30. Saadi S, Platt JL. Immunology of xenotransplantation. Life Sci 1998; 62: 365-387.
31. Park WD, Grande JP, Ninova D et al. Accommodation in ABO-incompatible kidney allografts. Am J Transplant 2003; 3: 952.
32. Bach FH, Ferran C, Hechenleitner P et al. Accommodation of vascularized xenografts: Expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997; 3: 196-204.
33. Salama AD, Delikouras A, Pusey CD et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260-269.